{"brief_title": "Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)", "brief_summary": "The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.", "condition": "Genital Warts", "intervention_type": "Biological", "intervention_name": "V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine", "description": "qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.", "arm_group_label": "4", "other_name": "Gardasil", "criteria": "Inclusion Criteria: - Healthy adolescents and pre-adolescents with no prior sexual history - Healthy women who have an intact uterus with lifetime history of 0-4 sexual partners Exclusion Criteria: - Prior Human Papillomavirus (HPV) vaccination - Prior abnormal Paps - Prior history of genital warts", "gender": "All", "minimum_age": "10 Years", "maximum_age": "23 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00092495.xml"}